Nuntida Salakshna1,2,3, Wilai Thanasarnaksorn1,2,3, Thanan Supasiri1,2,3. 1. Dr. Thanasarnaksorn is with the Samitivej Esthetics Institute, Samitivej Sukhumvit Hospital, and the Division of Dermatology, Department of Medicine, Faculty of Medicine at Ramathibodi Hospital of Mahidol University in Bangkok, Thailand. 2. Dr. Salakshna is with the Samitivej Esthetics Institute, Samitivej Chinatown Hospital in Bangkok, Thailand and the Science Division at Mahidol University International College in Nakhon Pathom, Thailand. 3. Dr. Supasiri is with the Life Center, Samitivej Sukhumvit Hospital, and the Department of Preventive and Social Medicine, Faculty of Medicine at Chulalongkorn University in Bangkok, Thailand.
Abstract
BACKGROUND: Botulinum toxin type A (BTxA) is used for cosmetic procedures, but its use for nasal dorsum augmentation has, to our knowledge, never been studied. OBJECTIVE: Here, we describe a method for using BTxA injection for nasal dorsum augmentation. METHODS: This was a pilot study. Participants aged 20 to 60 years were recruited and injected with BTxA in the upper nasal area with either Xeomin® (Merz Pharmaceuticals GmbH, Frankfurt, Germany) or Dysport® (Galderma Laboratories, Fort Worth, Texas). The primary outcome measured was the upper nasal area's volume change from baseline, calculated using a Quantificare camera (San Francisco, California). The volumizing effect was subjectively graded by two blinded dermatologists and participants, and pain scores and adverse events were recorded. RESULTS: Fourteen participants, including two men and 12 women, aged 35.78±9.16 years were recruited. Overall, the volume of the upper nasal area increased after BTxA injection (p<0.001). The volume increase immediately and, at one week after injection, presented a statistically significant difference from baseline, with median (interquartile range) volume differences of 0.095mL (0.010-0.205; p<0.001) and 0.095mL (0.0475-0.155; p<0.001), respectively. Two blinded dermatologists and all participants observed volumizing of the nasal dorsum. The effect appeared to last for one month. CONCLUSION: This study suggests that injecting BTxA in the upper nasal area is a convenient, minimally invasive technique with minimal side effects for nasal dorsum augmentation.
BACKGROUND: Botulinum toxin type A (BTxA) is used for cosmetic procedures, but its use for nasal dorsum augmentation has, to our knowledge, never been studied. OBJECTIVE: Here, we describe a method for using BTxA injection for nasal dorsum augmentation. METHODS: This was a pilot study. Participants aged 20 to 60 years were recruited and injected with BTxA in the upper nasal area with either Xeomin® (Merz Pharmaceuticals GmbH, Frankfurt, Germany) or Dysport® (Galderma Laboratories, Fort Worth, Texas). The primary outcome measured was the upper nasal area's volume change from baseline, calculated using a Quantificare camera (San Francisco, California). The volumizing effect was subjectively graded by two blinded dermatologists and participants, and pain scores and adverse events were recorded. RESULTS: Fourteen participants, including two men and 12 women, aged 35.78±9.16 years were recruited. Overall, the volume of the upper nasal area increased after BTxA injection (p<0.001). The volume increase immediately and, at one week after injection, presented a statistically significant difference from baseline, with median (interquartile range) volume differences of 0.095mL (0.010-0.205; p<0.001) and 0.095mL (0.0475-0.155; p<0.001), respectively. Two blinded dermatologists and all participants observed volumizing of the nasal dorsum. The effect appeared to last for one month. CONCLUSION: This study suggests that injecting BTxA in the upper nasal area is a convenient, minimally invasive technique with minimal side effects for nasal dorsum augmentation.
Authors: Steven Liew; Terrence Scamp; Mauricio de Maio; Michael Halstead; Nicole Johnston; Michael Silberberg; John D Rogers Journal: Aesthet Surg J Date: 2016-06-14 Impact factor: 4.283